3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Mantle-Cell
9
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, B-Cell
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Hematologic Diseases
1
Heart Failure
1
Burkitt Lymphoma
1
Anemia, Hemolytic, Autoimmune
1
Interventions
Cyclophosphamide
14
fludarabine
8
Rituximab
6
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Vincristine
4
Doxorubicin
4
Dexamethasone
4
zanubrutinib
3
Prednisone
3
Nivolumab
3
Etoposide
3
tazemetostat
2
tafasitamab
2
pirtobrutinib
2
pembrolizumab
2
glofitamab
2
etoposide phosphate
2
cemiplimab
2
acalabrutinib
2
Leukapheresis
2
Immunotherapy, Adoptive
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cisplatin
2
Cell- and Tissue-Based Therapy
2
Biopsy
2
venetoclax
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
acalabrutinib
×
30 days
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled